136 related articles for article (PubMed ID: 23468226)
1. Timing of factor VIIa in liver transplantation impacts cost and clinical outcomes.
Scheffert JL; Taber DJ; Pilch NA; McGillicuddy JW; Baliga PK; Chavin KD
Pharmacotherapy; 2013 May; 33(5):483-8. PubMed ID: 23468226
[TBL] [Abstract][Full Text] [Related]
2. Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation.
Hollis AL; Lowery AV; Pajoumand M; Pham SM; Slejko JF; Tanaka KA; Mazzeffi M
Ann Card Anaesth; 2016; 19(3):418-24. PubMed ID: 27397445
[TBL] [Abstract][Full Text] [Related]
3. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma.
Stein DM; Dutton RP; Kramer ME; Scalea TM
J Trauma; 2009 Jan; 66(1):63-72; discussion 73-5. PubMed ID: 19131807
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.
Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF
Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457
[TBL] [Abstract][Full Text] [Related]
5. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
Chapman AJ; Blount AL; Davis AT; Hooker RL
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
[TBL] [Abstract][Full Text] [Related]
6. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
7. Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery.
Harper PC; Smith MM; Brinkman NJ; Passe MA; Schroeder DR; Said SM; Nuttall GA; Oliver WC; Barbara DW
J Cardiothorac Vasc Anesth; 2018 Feb; 32(1):151-157. PubMed ID: 29217234
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven
Marsh K; Green D; Raco V; Papadopoulos J; Ahuja T
Ther Adv Cardiovasc Dis; 2020; 14():1753944720924255. PubMed ID: 32449469
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Factor VIIa Is Associated With Increased Thrombotic Complications in Pediatric Cardiac Surgery Patients.
Downey L; Brown ML; Faraoni D; Zurakowski D; DiNardo JA
Anesth Analg; 2017 May; 124(5):1431-1436. PubMed ID: 28319507
[TBL] [Abstract][Full Text] [Related]
10. Surgery in patients with congenital factor VII deficiency - a single center study.
Szczepanik A; Wiszniewski A; Oses-Szczepanik A; Dąbrowski W; Pielaciński K; Misiak A
Pol Przegl Chir; 2018 May; 90(5):1-5. PubMed ID: 30426948
[TBL] [Abstract][Full Text] [Related]
11. Low-dose recombinant factor VIIa for reversing coagulopathy in patients with isolated traumatic brain injury.
Yuan Q; Wu X; Du ZY; Sun YR; Yu J; Li ZQ; Wu XH; Mao Y; Zhou LF; Hu J
J Crit Care; 2015 Feb; 30(1):116-20. PubMed ID: 25092615
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients.
Brown CV; Foulkrod KH; Lopez D; Stokes J; Villareal J; Foarde K; Curry E; Coopwood B
J Trauma; 2010 Feb; 68(2):348-52. PubMed ID: 20154547
[TBL] [Abstract][Full Text] [Related]
13. Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.
Pham HP; Hsu SX; Parker-Jones S; Samstein B; Diuguid D; Schwartz J
Vox Sang; 2014 Jan; 106(1):75-82. PubMed ID: 23815226
[TBL] [Abstract][Full Text] [Related]
14. [The use of recombinant activated factor VII for blood loss after cardiovascular surgery].
Gong ZY; Gao CQ; Xiao CS; Li BJ; Ma XH; Zhang CM
Zhonghua Wai Ke Za Zhi; 2008 Oct; 46(19):1497-501. PubMed ID: 19094631
[TBL] [Abstract][Full Text] [Related]
15. Very low-dose recombinant Factor VIIa administration for cardiac surgical bleeding reduces red blood cell transfusions and renal risk: a matched cohort study.
Cotter E; Sharma A; Campton A; Gao G; He J; Wirtz K; Zorn T; Flynn BC
Blood Coagul Fibrinolysis; 2021 Oct; 32(7):473-479. PubMed ID: 34650021
[TBL] [Abstract][Full Text] [Related]
16. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion.
Perkins JG; Schreiber MA; Wade CE; Holcomb JB
J Trauma; 2007 May; 62(5):1095-9; discussion 1099-101. PubMed ID: 17495707
[TBL] [Abstract][Full Text] [Related]
17. A Propensity-Score Matched Analysis on Outcomes Using Recombinant Activated Factor VII in Pediatric Cardiac Surgery.
Li Y; Zhao W; Luo Q; Wu X; Ding J; Yan F
J Cardiothorac Vasc Anesth; 2019 May; 33(5):1269-1275. PubMed ID: 30795967
[TBL] [Abstract][Full Text] [Related]
18. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7).
Hacquard M; Durand M; Lecompte T; Boini S; Briançon S; Carteaux JP
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1320-7. PubMed ID: 21550261
[TBL] [Abstract][Full Text] [Related]
19. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
[TBL] [Abstract][Full Text] [Related]
20. Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation.
Kaliciński P; Markiewicz M; Kamiński A; Laniewski P; Ismail H; Drewniak T; Szymczak M; Nachulewicz P; Jezierska E
Pediatr Transplant; 2005 Jun; 9(3):299-304. PubMed ID: 15910384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
